Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 7
2015 30
2016 36
2017 31
2018 23
2019 33
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM. Langer-Gould AM. Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Continuum (Minneap Minn). 2019. PMID: 31162316 Review.
Highly Aggressive Multiple Sclerosis.
Bowen JD. Bowen JD. Continuum (Minneap Minn). 2019 Jun;25(3):689-714. doi: 10.1212/CON.0000000000000731. Continuum (Minneap Minn). 2019. PMID: 31162312 Review.
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A; NTD Study Group. Braune S, et al. J Neurol. 2018 Dec;265(12):2980-2992. doi: 10.1007/s00415-018-9083-5. Epub 2018 Oct 16. J Neurol. 2018. PMID: 30327931 Free PMC article.
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Rommer PS, Zettl UK. Rommer PS, et al. Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Expert Opin Pharmacother. 2018. PMID: 29528247 Review.
Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.
Gross RH, Corboy JR. Gross RH, et al. Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Continuum (Minneap Minn). 2019. PMID: 31162313 Review.
Gut microbiota in multiple sclerosis: possible influence of immunomodulators.
Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Venkatesan A, Fraser CM, Mowry EM. Cantarel BL, et al. J Investig Med. 2015 Jun;63(5):729-34. doi: 10.1097/JIM.0000000000000192. J Investig Med. 2015. PMID: 25775034 Free PMC article.
Glatiramer acetate attenuates renal ischemia reperfusion injury in rat model.
Nezamoleslami S, Sheibani M, Dehpour AR, Mobasheran P, Shafaroodi H. Nezamoleslami S, et al. Exp Mol Pathol. 2020 Feb;112:104329. doi: 10.1016/j.yexmp.2019.104329. Epub 2019 Nov 4. Exp Mol Pathol. 2020. PMID: 31697931
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
McKeage K. McKeage K. CNS Drugs. 2015 May;29(5):425-32. doi: 10.1007/s40263-015-0245-z. CNS Drugs. 2015. PMID: 25906331 Review.
Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H. Wijnands JMA, et al. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30. J Neurol Neurosurg Psychiatry. 2018. PMID: 29602795
Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.
Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M. Baruch K, et al. Nat Commun. 2015 Aug 18;6:7967. doi: 10.1038/ncomms8967. Nat Commun. 2015. PMID: 26284939 Free PMC article.
139 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback